Home » Topics » Disease categories and therapies » Urology

Urology
RSS

Fesoterodine superior to tolterodine in overactive bladder trial

April 26, 2006

No serious side effects in ongoing phase II study of NX-1207

April 26, 2006

Detrusitol receives Japanese approval for overactive bladder

April 25, 2006

ILY-101 completes phase I trial for hyperphosphatemia

April 25, 2006

Novel agent for the management of acute renal failure in sepsis

April 24, 2006

Vesicare approved as first drug for overactive bladder in Japan

April 21, 2006

Novel agents for urological disorders disclosed in recent patent literature

April 20, 2006

Pfizer to acquire rights to fesoterodine for overactive bladder

April 20, 2006

Targeting the mTOR pathway -- a promising therapeutic approach in polycystic kidney disease

April 19, 2006

Celecoxib investigated in acute renal colic

April 10, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 29, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Will Ovid’s golden age of KCC2 metamorph CNS?
BioWorld
The “deep dive” April 8 by Ovid Therapeutics Inc. into potassium-chloride co-transporter 2 (KCC2) research included company officials and independent experts in...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...